pipette
ESEspañol

Pathogenic Mitofusin 2 variants causing myopathy drive endosomal mtDNA release and inflammation

M. Zaman, J. David, A. Mehrabi, C. Chute, J. Deng, T. Soule, L. Wiseman, C. N. Antonescu, P. Colarusso, G. Pfeffer, T. Shutt

PreprintReal-world use

In the authors' words

Pathogenic variants in Mitofusin2 (MFN2) cause the peripheral neuropathy Charcot-Marie-Tooth Type IIA (CMT2A), with a subset of patients presenting with myopathy. Yet how MFN2 dysfunction causes these phenotypes remains mechanistically undefined. Here, we identify a conserved pathomechanism in MFN2-linked myopathy variants, where mitochondrial DNA is released into RAB5 early endosomes, robustly activating TLR9 and cGAS-STING inflammatory signaling. We further show that MFN2 dysfunction drives two mechanistically distinct pools of extra-mitochondrial mtDNA, one in endosomes and the other present mitochondrial-derived vesicles (MDVs). These two pools of released mtDNA can be distinguished based on their size, with endosomal mtDNA forming larger puncta than mtDNA present in MDVs. Finally, we describe that pharmacological activation of the integrated stress response reduces both pools of extra-mitochondrial mtDNA. Together, our work defines a conserved cellular phenotype linking MFN2 dysfunction to myopathy and suggests a tractable therapeutic strategy for mtDNA release-associated pathologies.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, September 30. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.22.26363493